RxDoctor Payments DataLook up a doctor →

Mohammad Diab, MD

Dermatology · West Chester, OHNPI 1194767087

Payments from drug & device makers

$67,150in general payments, 2019–2025

Across 978 payments — averaging $68.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$36K
  • Bristol Myers Squibb$8K
  • Sun Pharmaceutical Industries Inc.$7K
  • E.r. Squibb & Sons, L.L.C.$4K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • plus $8K from 30 others

What the payments were for

  • Consulting fees$2,7164%
  • Speaking & faculty fees$45,23867%
  • Travel & lodging$1,7043%
  • Food & beverage$16,72225%
  • Education$7711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,150 in reported general payments places this provider in the 85th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$334,757
Medicare patients
808
Services billed
4,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$275,202
TremfyaGuselkumab12$162,002
OtezlaApremilast16$82,490
Dupixent PenDupilumab21$76,755
Clobetasol Propionate229$10,440
SantylCollagenase Clostridium Hist.12$8,429
Fluorouracil102$8,321
Tacrolimus25$3,189
Mycophenolate Mofetil11$2,649
Triamcinolone Acetonide192$2,467
Metronidazole54$2,008
Ketoconazole104$1,731
Acitretin15$1,590
Doxycycline Monohydrate88$1,496
Mupirocin173$1,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,853$162,00212 claims
AmgenOtezla$35,791$82,49016 claims
Smith+NephewSantyl$29$8,42912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 460 dermatology providers in Ohio.

Other dermatology in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →